Genflow Biosciences plc (LSE:GEN) has progressed preclinical development programmes targeting the biological ageing process, according to regulatory announcements delivered in 2026. The London-headquartered biotechnology company is the first longevity-focused biopharmaceutical enterprise to list on the London market. Genflow specialises in the development of adeno-associated …
On 13 October 2026, Molecule Group (LSE:MOL) disclosed that Brendan O'Brien, its chief operating officer, had bought shares in the company. The dealing was disclosed in a notification of a transaction by a person discharging managerial responsibilities (PDMR), as required under the UK Market …
Solvonis Therapeutics plc (LSE:SVNS) said on 13 October 2026 that it had signed a memorandum of understanding (MoU) with two Portuguese parties to assess the potential expansion of MORE-KARE, the Phase 3 trial of its SVN-001 treatment, into Portugal.
Verici Dx published two announcements on 13 October 2026. The first confirmed completion of a fundraise of £8.75m, made up of a placing announced on 8 October 2026 and a retail offer through the WRAP platform launched on 9 October 2026. The company said …
On 12 October 2026 Oxford Nanopore Technologies plc (LSE:ONT) published a notification of a transaction by a person discharging managerial responsibilities (PDMR) under the UK Market Abuse Regulation. The PDMR is Adrian Hennah, a non-executive director of the company.
Syncona Limited, the life sciences investor, published an announcement on 12 October 2026. Beacon Therapeutics, one of its portfolio companies, presented results from the pivotal Phase II/III VISTA trial as a late-breaking oral presentation during Retina Subspecialty Day at the American Academy of Ophthalmology …
Tristel develops disinfectants based on chlorine dioxide chemistry, used to decontaminate medical devices such as ultrasound probes and endoscopes. It is based at Snailwell near Cambridge, employs about 270 people, sells in more than 40 countries and has been quoted on AIM since 2005, …
The boards announced the agreed terms on 25 June 2026. H.B. Fuller Medical Adhesive Technologies Inc., a wholly owned subsidiary of H.B. Fuller, will pay 285 pence in cash for each AMS share, valuing the fully diluted equity at about £659m and the enterprise …
Bioventix creates antibodies that other companies build into their diagnostic analysers, and it earns revenue from antibody sales and royalties. Its established products include vitamin D and troponin antibodies. A newer interest is neurology, where its antibodies are used in research assays for Tau, …
Craneware sells revenue-cycle and pricing software to US hospitals. Growth in recent years has been tied partly to the 340B drug discount programme, where it expected customers to pursue so-called Shelter opportunities. According to the chair, Dr Will Whitehorn, the year did not close …